Ratos completes offer to shareholders and convertible debenture holders in Biolin Scientific


This information is disclosed in accordance with the Securities Markets Act and
   NASDAQ OMX Stockholm's rules regarding public offers on the stock market.

This press release may not be distributed, directly or indirectly, in or into,
Australia, Canada, Japan, New Zealand, South Africa, Switzerland or the United
States of America. The Offer is not being made to (and acceptances will not be
accepted from) persons in those countries or in any other country where the
making of the Offer, the distribution of this press release or acceptance of the
Offer requires further offer documents, filings or other measures in addition to
those required by Swedish law.
Shareholders and convertible debenture holders representing 16 811 845 shares in Biolin Scientific, corresponding to 63,25%[1] of the capital and votes, have accepted Ratos's offer. This means that Ratos now, including the shares acquired by Ratos through the agreements Ratos entered into with Farstorp Invest AB and Bo Håkansson prior to the announcement of the offer, holds a total of 24 424 074 shares and convertibles in Biolin Scientific, corresponding to 91,89%[1] of the capital and votes. Since all terms and conditions for completion of the offer have thus been fulfilled, Ratos has decided to complete the offer. Ratos has also decided to extend the acceptance period until 12 January 2011.
On 29 November 2010, Ratos announced an offer to shareholders and convertible debenture holders in Biolin Scientific to acquire all shares and convertibles for a cash payment of SEK 11.50 for each share and each convertible debenture. The acceptance period for the offer was 1-21 December 2010.
In order to allow participation in the offer for those shareholders and convertible debenture holders who have not yet accepted the offer, the acceptance period will be extended until 17.00 CET on 12 January 2011.
For the shareholders and convertible debenture holders in Biolin Scientific who accepted the offer during the ordinary acceptance period, settlement is expected to commence on 28 December 2010. For those who accept the offer during the extended acceptance period, settlement is expected to commence on 19 January 2011. Since the offer is now unconditional, shareholders and convertible debenture holders who accept the offer will not be entitled to withdraw their acceptances.
Since Ratos holds more than 90% of the capital and votes in Biolin Scientific, Ratos intends shortly to initiate compulsory acquisition of the remaining shares in Biolin Scientific and to promote a delisting of Biolin Scientific's shares from NASDAQ OMX Stockholm.
[1] Calculated after full dilution.
For further information, please contact: Arne Karlsson, CEO, through Nina Aggebäck, +46 76 125 09 01 Emma Rheborg, Head of Corporate Communications and IR, +46 733 80 22 63
Financial calendar from Ratos:
Year-end report 2010 17 February 2011 Annual General Meeting 2011 5 April 2011 Interim Report January - March 2011 5 May 2011 Interim Report January - June 2011 19 August 2011 Interim Report January - September 2011    9 November 2011

Ratos is a private equity conglomerate. The company's mission is to maximise shareholder value over time through the professional, active and responsible exercise of its ownership role in primarily medium to large unlisted Nordic companies. Ratos's holdings include AH Industries, Anticimex, Arcus Gruppen, Bisnode, Camfil, Contex, DIAB, EuroMaint, GS-Hydro, Hafa Bathroom Group, HL Display, Inwido, Jøtul, KVD Kvarndammen, Lindab, Medisize, Mobile Climate Control, SB Seating, Stofa, Superfos and Other holdings. Ratos is listed on NASDAQ OMX Stockholm and market capitalisation amounts to approximately SEK 40 billion.